What can we do for you?
No. 2 on the A-List 2024
Ropes & Gray has been ranked No. 2 on The American Lawyer’s A-List—our eighth consecutive top-three ranking on the prestigious list.
The American Lawyer’s 2024 Pharma and Health Care Corporate Practice of the Year
Ropes & Gray’s life sciences and healthcare teams delivered exceptional results for clients, steering transformative deals and facilitating over 110 complex licensing and collaboration transactions with an aggregate value of $55 billion.
Latest Insights
Alert
U.S. Private Equity Market Recap - March 2025
Read our latest insights into the U.S. private equity market. We cover monthly deal activity and size, fundraising, exits, leveraged loans, and a look ahead.
Alert
Federal Circuit Expands the Scope of Investments That Can Satisfy the ITC’s Domestic Industry Requirement—Will More Section 337 Investigations Follow?
On March 5, 2025, the United States Court of Appeals for the Federal Circuit issued a precedential opinion that will change the way the U.S. International Trade Commission addresses the threshold “domestic industry requirement” in Section 337 unfair import investigations
Alert
USPTO Rescinds Interim Guidance on Discretionary Denials
On February 28, 2025, the U.S. Patent and Trademark Office (“USPTO”) rescinded its June 21, 2022 Memorandum entitled “Interim Procedure for Discretionary Denials in AIA Post-Grant Proceedings with Parallel District Court Litigation” (see prior Alert).

United in the Fight Against Cancer
Through our work with clients, public service and support of our own community, Ropes & Gray is committed to the battle against cancer.
Ropes & Gray
By the numbers
0+
Attorneys worldwide
0
Offices
0+
2024 pro bono hours
0
Consecutive years on A-List of elite firms
